# Likarda

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/likarda

- Industry: Pharmaceuticals
- Headquarters: Kansas City, US
- Website: www.likarda.com
- Total disclosed funding: $4M
- Latest round: Series A (Aug 28, 2017)
- Investors on record: 1

## About

Likarda, LLC focuses on the advancement of cell therapy delivery systems using proprietary technology, enhancing the efficacy of therapeutic applications for chronic diseases.Likarda, LLC specializes in developing innovative solutions for cell therapy delivery. Founded in 2012 in Kansas City, US, by Karthik Ramachandran and Lisa Stehno-Bittel, the company raised USD 4.00 mn in Series A funding from Werth Family Investment Associates in August 2017, which is the total amount raised to date. The company has pursued collaborations with pharmaceutical and biotechnology firms to enhance therapeutic delivery methods.Likarda specializes in the development of innovative cell therapy delivery systems, primarily through its proprietary Core Shell Spherification® (CSS) technology. This unique platform is designed to improve the potency and efficacy of various cell therapies by utilizing customizable hydrogels that encapsulate therapeutic cells. The hydrogels protect cells from immune system attacks and ensure they remain localized at target sites within the body, enhancing treatment outcomes for chronic and fatal diseases. Likarda's products are aimed at pharmaceutical companies, biotechnology firms, and research institutions that require advanced methods for delivering cell therapies, serving clients across North America, Europe, and Asia.Likarda's revenue generation model is primarily centered on partnerships and collaborations with biotechnology and pharmaceutical companies, which involve contract research agreements and customized development projects. The company offers bespoke hydrogel products tailored to specific therapeutic applications. Transactions are structured based on project scope, including milestone payments aligned with research and development phases. Flagship products, such as their specialized hydrogel formulations, are integral to these collaborations, providing unique solutions designed to enhance the effectiveness of therapies. This structure fosters long-term client relationships, encouraging repeat business.Likarda is focused on expanding its product offerings and entering new markets. The company is developing additional hydrogel products aimed at addressing specific therapeutic challenges, with anticipated releases aligned with ongoing research collaborations. Recent funding of USD 4.00 mn from Series A will support these initiatives, enhancing their capacity for growth in North America, Europe, and Asia, with a strategic focus on increasing market share by 2025.

## Funding rounds

- Series A, Aug 28, 2017, $4M — Werth Family Investment Associates

## Investors

- Werth Family Investment Associates (https://capitalatlas.ai/funds/werth-family-investment-associates) — Series A